Remove .Net Remove 2017 Remove Develop Remove Report
article thumbnail

RA Medical Systems Files For $86.25M IPO

socalTECH

Carlsbad-based RA Medical Systems , which develops cardiovascular and dermatology catheters and excimer lasers, has filed for an IPO, saying that it is looking to raise up to $86.25M in an IPO on the New York Stock Exchange. The reported a net loss of $17.765M on net revenues of $5.87M for its year ended December 31, 2017.

.Net 100
article thumbnail

Activision Blizzard To Slash Almost 800 Employees

socalTECH

Santa Monica-based game developer Activision Blizzard says it is slashing 8 percent of its staff, or nearly 800 employees, as a part of a restructuring effort at the company. The move comes even as Activions Blizzard reported record net revenues in 2018 of $7.50 billion it had in revenues for 2017. bllion, up from the $7.02

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

—Colorado-based Webroot said in September it had acquired CyberFlow Analytics , the 2013 startup developing analytic software and machine learning technology to monitor the data flowing in and out of networks for anything that looks out of the ordinary. I widened my net this year. Webroot withheld terms of the deal.).

article thumbnail

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. STAT found the figures in Editas’s quarterly earnings report. Talk about sacrifice.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

—South San Francisco, CA-based Denali Therapeutics, with ambitions to develop drugs for several neurodegenerative diseases, bagged $130 million in a Series B and unveiled a series of deals. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017. Alex Lash contributed to this report. Morgan party.

Pricing 40